Nelarabine

Pronunciation: pronunciation varies by local usage.

Generic name: nelarabine
Brand names: Arranon
Drug class: Nucleoside metabolic inhibitor
Form: Injection for intravenous infusion
Route: Intravenous infusion
Legal status: Prescription-only medicine

Availability and supply rules vary by country

Trade names by country: United States · Canada

What nelarabine is and how it works

Nelarabine is a nucleoside metabolic inhibitor chemotherapy given by intravenous infusion for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adults and children age 1 year and older whose disease has not responded to or has relapsed after at least two chemotherapy regimens. (1)

This is a cytotoxic agent used under the direction of an oncologist. It is associated with potentially serious neurologic and hematologic side effects and requires close monitoring.

Mechanism of action: how nelarabine works

Nelarabine is a nucleoside metabolic inhibitor. (1)

What nelarabine is used for

T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

Nelarabine is indicated for the treatment of adults and children aged 1 year and older with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed after at least two chemotherapy regimens. (1)

Before taking nelarabine

Do not take / not appropriate for

Do not receive live vaccines while on nelarabine, as your immune system may be compromised and you could develop a serious infection. (all patients) (1)

Tell your clinician about

Any new or worsening numbness, tingling, weakness, seizures, or unusual sleepiness.
If you are pregnant, planning pregnancy, or breastfeeding.
All medicines you are taking, especially pentostatin or other adenosine deaminase inhibitors.
Any planned vaccinations or recent infections.
If you have liver or kidney problems.

(1)

How to take nelarabine

Nelarabine is administered as an intravenous infusion by a healthcare professional in a hospital or clinic setting.
The exact dose and frequency are determined by the oncologist based on indication, body surface area, and the specific regimen (adults: days 1, 3, 5 of a 21-day cycle; pediatric: 5 consecutive days of a 21-day cycle).
You will be monitored closely before, during, and after each infusion for side effects, especially neurologic changes.
Do not attempt to self-administer or alter the dosing schedule yourself.

(1)

Procedures and treatment changes

Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)

Missed dose

If you think a scheduled infusion has been missed, contact your oncology team immediately. They will reschedule your treatment as needed.

Overdose

If an overdose is suspected, the oncology team will provide supportive care and monitoring. Contact your oncologist or emergency services immediately if you experience severe neurologic symptoms or signs of infection. (1)

Side effects

Nelarabine is associated with significant side effects, particularly neurologic and hematologic toxicities. Many side effects require immediate medical attention.

Anemia, thrombocytopenia, neutropenia

What to notice: Unusual fatigue, shortness of breath, easy bruising, bleeding, fever, or signs of infection.

What to do: Report to your oncology team. Regular blood tests will monitor your counts. (1)

Fatigue and nausea

What to notice: Persistent tiredness, lack of energy, feeling sick to your stomach.

What to do: Discuss supportive care options (e.g., anti-nausea medications) with your team. (1)

Neurologic symptoms

What to notice: Somnolence (excessive sleepiness), dizziness, numbness, tingling, weakness, headache, paresthesia (unusual skin sensations).

What to do: Report any new or worsening neurologic symptoms immediately. Your oncologist may adjust or stop treatment. (1)

Severe neurologic reactions

What to notice: Seizures, altered mental state, severe weakness, paralysis, ascending weakness (like Guillain-Barré syndrome), or loss of consciousness.

What to do: Seek emergency medical care. The oncology team will discontinue nelarabine for Grade 2 or greater toxicity. (1)

Tumor lysis syndrome

What to notice: Abnormal heart rhythm, muscle cramps, seizures, decreased urine output, or extreme fatigue.

What to do: Contact your oncology team immediately. Prophylactic measures (hydration, allopurinol) may be used, but symptoms can still occur. (1)

Serious warnings

Severe neurologic adverse reactions (Boxed Warning) — emergency

Symptoms: Altered mental status, severe somnolence, convulsions, peripheral neuropathy (numbness, weakness, paralysis), ascending weakness, demyelination.

Action: Report any new or worsening neurologic symptoms immediately to your oncology team. The drug may be discontinued. Seek emergency care for seizures or loss of consciousness. Full recovery may not occur after stopping. (1)

Interactions

Medicine or test	Effect	Action
Pentostatin and other adenosine deaminase inhibitors	Increased risk of severe toxicity; the combination is not recommended.	Avoid concurrent use. Inform your oncologist of all medications you are taking. (1)
Live vaccines	May cause severe or fatal infections due to immunosuppression.	Avoid live vaccines during treatment. Consult your oncologist about appropriate vaccination timing. (1)

Pregnancy, breastfeeding, kidney/liver function, age

Pregnancy

Nelarabine can cause fetal harm. Females of reproductive potential should use effective contraception during treatment. Males should use condoms during treatment and for 3 months after the last dose. (1)

Lactation

Breastfeeding is not recommended during treatment. (1)

Renal impairment

No dose adjustment is needed for CrCl ≥50 mL/min. There is insufficient data for CrCl <50 mL/min; closer monitoring is recommended. (1)

Hepatic impairment

Not studied; use with caution and monitor closely in severe hepatic impairment. (1)

Pediatric use

Nelarabine is indicated for children aged 1 year and older. Dosing and safety profiles differ from adults; a pediatric-specific regimen is used. (1)

Monitoring

Before starting

Baseline neurologic examination, complete blood count, renal and hepatic function tests.

During treatment

Frequent monitoring for neurologic toxicity with each visit.
Regular blood counts to detect hematologic toxicity.
Hydration and uric acid prophylaxis (allopurinol) may be used to prevent tumor lysis syndrome.
Immediate reporting of new neurologic symptoms is essential; treatment may be modified.

(1)

Storage

Nelarabine is stored and handled by healthcare professionals as a hazardous drug. Vials are kept at 20–25°C with excursions permitted to 15–30°C. Diluted solution is stable for up to 8 hours at room temperature up to 30°C in PVC or glass containers. Patients do not store or handle this medication.

Professional information

Clinician-facing context only. Use the current local label for dosing and monitoring protocols.

All regions

Indication: Relapsed or refractory T-ALL/T-LBL

Dose summary: Adults: 1,500 mg/m² IV over 2 hours on days 1, 3, 5, every 21 days. Pediatric: 650 mg/m² IV over 1 hour daily for 5 consecutive days, every 21 days.

Renal context: No dose adjustment for CrCl ≥50 mL/min; insufficient data below 50 mL/min, monitor closely. (1)

Mechanism of action

Hepatic guidance

Hepatic impairment has not been evaluated; close monitoring recommended in severe impairment.

Overdose note

No specific overdose information is provided; management is supportive with close monitoring for neurologic and hematologic toxicity. (1)

Frequently asked questions

What is nelarabine used for?

Nelarabine is used to treat T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adults and children aged 1 year and older whose disease has not responded to or has relapsed after at least two chemotherapy regimens. (1)

What is the most important warning for nelarabine?

Nelarabine carries a boxed warning for severe neurologic reactions, including altered mental state, seizures, peripheral neuropathy, and weakness. Full recovery may not always occur after stopping treatment. (1)

Can I receive live vaccines while on nelarabine?

No. Live vaccines should be avoided because nelarabine can weaken the immune system, increasing the risk of serious infections. (1)

Can I store or handle nelarabine at home?

No. Nelarabine is a hazardous drug that is stored, prepared, and administered only by trained healthcare professionals in a hospital or clinic setting. (1)

What is the mechanism of action of nelarabine?